Eloxx Pharmaceuticals, Inc. Market Cap ($54.29 Million)
Market Cap & Net Worth: Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. market cap. Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has a market capitalization of $54.29 Million ($54.29 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21417 globally and #4806 in its home market, demonstrating a 2.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eloxx Pharmaceuticals, Inc.'s stock price $13.45 by its total outstanding shares 4036459 (4.04 Million). Also see Eloxx Pharmaceuticals, Inc. (ELOX) cash flow conversion for how efficiently the company converts equity into cash flow.
Eloxx Pharmaceuticals, Inc. Market Cap History (2026–2026)
Eloxx Pharmaceuticals, Inc. market cap history from 2026 to 2026. Data shows growth from $54.29 Million to $54.29 Million (0.00% CAGR). Check Eloxx Pharmaceuticals, Inc. stock price for real-time trading data and today's change.
Eloxx Pharmaceuticals, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eloxx Pharmaceuticals, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ELOX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ELOX by Market Capitalization
Companies near Eloxx Pharmaceuticals, Inc. in the global market cap rankings as of November 1, 2026. Also see how large is Eloxx Pharmaceuticals, Inc.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Eloxx Pharmaceuticals, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Eloxx Pharmaceuticals, Inc. (2026–2026)
Market capitalization of Eloxx Pharmaceuticals, Inc. from 2026 to today. Between 2026 and today, Eloxx Pharmaceuticals, Inc.'s market cap moved from $54.29 Million to $ 54.29 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $54.29 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Eloxx Pharmaceuticals, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.29 Million USD |
| MoneyControl | $54.29 Million USD |
| MarketWatch | $54.29 Million USD |
| marketcap.company | $54.29 Million USD |
| Reuters | $54.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more